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ABSTRACT
Introduction Patent ductus arteriosus (PDA) is the
most common cardiovascular problem that develops
in preterm infants and evidence regarding the best
treatment approach is lacking. Currently available medical
options to treat a PDA include indomethacin, ibuprofen or
acetaminophen. Wide variation exists in PDA treatment
practices across Canada. In view of this large practice
variation across Canadian neonatal intensive care units
(NICUs), we plan to conduct a comparative effectiveness
study of the different pharmacotherapeutic agents used to
treat the PDA in preterm infants.
Methods and analysis A multicentre prospective
observational comparative-effectiveness research study
of extremely preterm infants born <29 weeks gestational
age with an echocardiography confirmed PDA will be
conducted. All participating sites will self-select and
adhere to one of the following primary pharmacotherapy
protocols for all preterm babies who are deemed to require
treatment.
1. Standard dose ibuprofen (10 mg/kg followed by two
doses of 5 mg/kg at 24 hours intervals) irrespective of
postnatal age (oral/intravenous).
2. Adjustable dose ibuprofen (oral/intravenous) (10 mg/
kg followed by two doses of 5 mg/kg at 24 hours
intervals if treated within the first 7 days after birth.
Higher doses of ibuprofen up to 20 mg/kg followed by
two doses of 10 mg/kg at 24 hours intervals if treated
after the postnatal age cut-off for lower dose as per
the local centre policy).
3. Acetaminophen (oral/intravenous) (15 mg/kg every 6
hours) for 3–7 days.
4. Intravenous indomethacin (0.1–0.3 mg/kg intravenous
every 12–24 hours for a total of three doses).

Strengths and limitations of this study
►► The study will establish the safety and effectiveness

of commonly used patent ductus arteriosus (PDA)
treatment options in a large contemporary patient
cohort in Canada.
►► Use of an innovative research design like comparative effectiveness research will make the conduct
of such a large study feasible in a cost-efficient
fashion.
►► The study will examine clinical outcomes related to
PDA treatment practices in the real world, which will
inform future practice and reduce practice variability.
►► The observational nature of the study increases the
risk of bias from unmeasured confounding which
will be partially accounted for by the proposed analyses strategies.

Outcomes The primary outcome is failure of primary
pharmacotherapy (defined as need for further medical
and/or surgical/interventional treatment following an initial
course of pharmacotherapy). The secondary outcomes
include components of the primary outcome as well as
clinical outcomes related to response to treatment or
adverse effects of treatment.
Sites and sample size The study will be conducted in
22 NICUs across Canada with an anticipated enrollment of
1350 extremely preterm infants over 3 years.
Analysis To examine the relative effectiveness of the
four treatment strategies, the primary outcome will be
compared pairwise between the treatment groups using
χ2 test. Secondary outcomes will be compared pairwise
between the treatment groups using χ2 test, Student’s
t-test or Wilcoxon rank sum test as appropriate. To further
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BACKGROUND
The most common cardiovascular problem that infants
born extremely preterm experience early in life is a
patent ductus arteriosus (PDA).1 Prolonged patency
of the ductus arteriosus in extremely preterm infants
is associated with longer duration of endotracheal
mechanical ventilation, higher rates of death, chronic
lung disease (CLD), necrotising enterocolitis (NEC),
renal failure, intracranial haemorrhage and cerebral
palsy.1–7
Currently available options to treat a PDA include
cyclo-oxygenase inhibitor (COX-I) drugs such as indomethacin, ibuprofen or acetaminophen. Indomethacin
and ibuprofen act by inhibition of the COX enzyme
thereby leading to downregulation of PGE2, a potent
relaxant of the PDA.8 Recently, acetaminophen has
also emerged as a potential treatment option for PDA
closure. Acetaminophen is postulated to exert its action
through inhibition of the peroxidase enzyme thereby
leading to downregulation of PGE2 production.9 If one
course of medical therapy is ineffective in treating a
PDA then clinicians may try a second (and sometimes
a third) course of the same or a different medication.
If the PDA still remains symptomatic, then surgical or
interventional closure of the PDA is considered. Over
70 randomised clinical trials have been conducted
to date to explore the efficacy of the available treatment options to treat a symptomatic PDA, the results
of which have been summarised and updated on six
Cochrane Neonatal reviews.10–15 It has been shown that
COX-I drugs are effective in closing a PDA compared
with placebo.16 Based on the earlier placebo-controlled
trials, intravenous indomethacin was considered to
be the gold standard for PDA treatment.1 8 17 Subsequent randomised controlled trials (RCTs) suggest that
ibuprofen appears to be as effective as indomethacin
in closing a PDA while reducing the risk of NEC and
transient renal insufficiency.10 The dosage of ibuprofen
used in these RCTs were consistent and was therefore
referred to as standard dose ibuprofen (10 mg/kg
followed by 2 doses of 5 mg/kg at 24 hours intervals).10
Based on these studies, standard dose ibuprofen has
been increasingly used as the first choice for treatment
of a symptomatic PDA.
2

However, the generalisability of the results from the
clinical trials and consequently the effectiveness of
standard dose ibuprofen in real-world clinical practice
remains controversial.18 Systematic reviews of earlier
RCTs using standard dose ibuprofen had shown that
only 26%–29% of the treated infants fail primary pharmacotherapy.10 16 However, a recent Canadian study by
Dersch-Mills et al19 showed that failure rate with the first
course of ibuprofen was above 40%. Furthermore, the
primary pharmacotherapy failure rate for ibuprofen in
two recent RCTs comparing PDA treatment between 6–14
days versus expectant management were noted to be 57%
(PDA-TOLERATE trial; Clyman et al) and 80% (Sung et
al), respectively.20 21 This observed difference in effectiveness is likely due to the fact that infants in previous RCTs
were treated much earlier (median ~3 days) as compared
with real-world practice as well as in the more recently
conducted RCTs.20–23 Such observations seem congruent
with pharmacokinetic studies on ibuprofen dosage in
premature infants. Hirt et al24 showed that irrespective
of gestational age (GA), increasingly higher doses are
required with increasing postnatal age to achieve optimal
concentrations of ibuprofen for successful PDA closure.
One small RCT (n=70) (Dani 2012) compared high-dose
intravenous ibuprofen versus standard dose and found
a significant improvement in primary PDA closure rates
without increased incidence of oliguria or NEC.25 Similar
results have been obtained with high dose oral ibuprofen
in three other RCTs (Pourarian 2015 (n=60), Fesharaki
2012 (n=60) and Bagheri 2016 (n=129)).26–28 In the
systematic review and Bayesian network meta-
analysis
conducted by Mitra et al,16 it was found that higher doses
of ibuprofen were associated with a higher likelihood of
PDA closure vs standard doses of intravenous ibuprofen
or intravenous indomethacin. However, the effect estimates were derived from the four small trials mentioned
above which contributed only 157 infants for high dose
ibuprofen out of a total sample size of 4256 infants
thereby lowering the confidence in these estimates.
Furthermore, the mean GA of included infants in 3 out
of the above 4 trials were 30 weeks or more.26–28 Therefore, the effectiveness and safety of high-dose ibuprofen
in extremely preterm infants (<29 weeks GA) is largely
unknown precluding its universal adoption. The controversy around pharmacotherapeutic practices is evident
from the wide practice variation across Canada. A survey
conducted specifically to inform this project, through the
Canadian Neonatal Network (CNN) in 2019 identified
that 56% of the centres (14/25 respondents) use standard dose ibuprofen while 32% (8/25) use higher doses
of ibuprofen.
Controversy also exists on whether treatment of a PDA
actually improves clinical outcomes. Previous observational studies on PDA treatment trends in Canada show
that with conservative management strategies, clinical
outcomes are significantly better.29 However, residual
confounding cannot be completely ruled out in these
studies. For example, in a recent study comparing
Mitra S, et al. BMJ Open 2021;11:e050682. doi:10.1136/bmjopen-2021-050682
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examine differences in the primary and secondary outcomes between
the four groups, multiple logistic or linear regression models will be
applied for each outcome on the treatment groups, adjusted for potential
confounders using generalised estimating equations to account for within-
unit-clustering. As a sensitivity analysis, the difference in the primary and
secondary outcomes between the treatment groups will also be examined
using propensity score method with inverse probability weighting
approach.
Ethics and dissemination The study has been approved by the IWK
Research Ethics Board (#1025627) as well as the respective institutional
review boards of the participating centres.
Trial registration number NCT04347720.
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Specific aims
1. To compare the relative effectiveness of commonly used pharmacotherapeutic agents in extremely
preterm infants (<29 weeks GA) requiring treatment
for PDA in achieving successful PDA closure.
2. To evaluate the relative safety of commonly used pharmacotherapeutic agents in extremely preterm infants
(<29 weeks GA) requiring treatment for PDA on
patient-important clinical outcomes.
3. To understand the clinical relevance of PDA treatment
by comparing clinical characteristics and outcomes of
extremely preterm infants (<29 weeks GA) treated for
a PDA versus (1) a control group of extremely preterm
infants (<29 weeks GA) who were diagnosed with but
never treated for a PDA; (2) a reference group of extremely preterm infants (<29 weeks GA) not diagnosed
with a PDA.
Study hypotheses
(1) In preterm neonates <29 weeks GA with a PDA, use
of adjustable dose ibuprofen (as compared with standard dose ibuprofen or acetaminophen or indomethacin) is associated with higher PDA closure rate and
lower need for repeat medical treatment or surgical
PDA closure without increasing adverse effects; (2)
Preterm infants <29 weeks GA, treated for PDA, have
improved clinical outcomes compared with infants with
similar clinical and PDA characteristics who did not
receive treatment; (3) Preterm infants <29 weeks GA,
receiving PDA treatment have similar clinical outcomes
compared with infants with similar clinical characteristics not diagnosed with PDA.
Mitra S, et al. BMJ Open 2021;11:e050682. doi:10.1136/bmjopen-2021-050682

METHODS
Study design
Multicentre prospective observational comparative-
effectiveness research (CER) study planned to be
conducted over 3 years (January 2020 to December 2022).
Proposed study participants
All infants born at less than 29 weeks of gestation admitted
to participating sites will be included in the study. For
aims (1) and (2), the population of interest will be those
preterm infants<29 weeks gestational age (including
outborns) with echocardiography confirmed PDA who
will be treated according to attending team. For aim (3, i)
infants <29 weeks GA with echocardiography-confirmed
PDA but never received treatment will be included as the
control population. For aim (3, ii), infants <29 weeks GA
who were never diagnosed with PDA will be included as
the reference population. Infants who received prophylactic COX-I drugs in the first 24 hours after birth for
prevention of intraventricular haemorrhage will be
included. Any infant who received pharmacotherapy
for a clinically symptomatic PDA without prior echocardiographic confirmation of the presence of PDA will be
excluded from all analyses.
Interventions
Each site will choose one of the following four interventions as their initial pharmacotherapy for infants
requiring PDA treatment:
1. Standard dose ibuprofen (10 mg/kg followed by 2
doses of 5 mg/kg at 24 hours intervals) irrespective of
postnatal age (oral/intravenous).
2. Adjustable dose ibuprofen [Oral/intravenous) (10
mg/kg followed by two doses of 5 mg/kg at 24 hours
intervals if treated within the first 7 days after birth.
Higher doses of ibuprofen up to 20 mg/kg followed by
two doses of 10 mg/kg at 24 hours intervals if treated
after the postnatal age cut-off for lower dose as per the
local centre policy).
3. Acetaminophen (oral/intravenous) (15 mg/kg every 6
hours) for 3–7 days.
4. Intravenous indomethacin (0.1–0.3 mg/kg intravenous every 12–24 hours for a total of 3 doses).
Outcomes
The primary outcome is failure of primary pharmacotherapy (defined as need for further medical and/or
surgical/interventional treatment following an initial
course of pharmacotherapy). The secondary outcomes
include components of the primary outcome as well as
clinical outcomes that are related to response to treatment or adverse effects of treatment. The secondary
outcomes are: (1) Receipt of second course of pharmacotherapy; (2) Surgical/interventional PDA closure; (3)
CLD (defined as oxygen or respiratory support requirement at 36 weeks’ postmenstrual age or at discharge)31;
(4) NEC (stage 2 or greater)32; (5) Severe intraventricular haemorrhage (defined as Grade III-IV according to
Papile Criteria)33; (6) Definite sepsis (clinical symptoms
3
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PDA management outcomes in Canada and Japan by
Isayama et al,30 review of 6981 very low birth weight infants
(birth weight <1500 g) across CNN centres showed that
infants treated conservatively were more mature (mean
GA 27.4 (±2.1) vs 25.6 (±1.7) weeks), had higher birth
weight (mean birth weight 1019 (±257) vs 832 (±208)
g) and were clinically more stable at birth (% of infants
with Apgar score <7 at 5 min 33% vs 41%) compared with
infants who received pharmacotherapy and then went
on to receive surgical PDA ligation. Therefore, whether
non-
treatment of PDA across all extremely preterm
gestations irrespective of PDA size is the right approach
remains questionable, which in turn leads to large practice variation.
Based on the variation in practice with respect to
PDA treatment across Canadian neonatal intensive care
units (NICUs), our primary objective in this study is to
compare the different pharmacotherapeutic practices
aimed at closure of PDA and evaluate their impact on
clinical outcomes in extremely preterm infants (<29
weeks GA). Our secondary objective is to understand
the relevance of PDA treatment with respect to patient-
important clinical outcomes.

Open access

Study flow. PDA, patent ductus arteriosus.

and signs of sepsis and a positive bacterial culture in a
specimen obtained from normally sterile fluids or tissue
obtained at postmortem)34; (7) Stage 1 or greater AKI
(according to the Neonatal AKI KDIGO classification)35;
(8) Post-treatment serum bilirubin (maximum serum bilirubin (uMol/L) within 1 week of initiation of each course
of pharmacotherapy); (9) Maximum serum AST and ALT
(u/L) during treatment or within 1 week of treatment
completion; (10) All-cause mortality during hospital stay.
Study design and implementation
In this CER study, participating sites will self-select and
adhere to any one of the above pharmacotherapy protocols for all preterm babies who are deemed to require
treatment for a PDA (figure 1). Presence of a PDA on
echocardiography prior to starting pharmacotherapy will
be documented for an infant to be eligible. However, to
mimic the real-world scenario, clinical and echocardiographic criteria for initiating treatment will be left up
to the attending medical team. If the PDA is deemed to
remain symptomatic after the first course of pharmacotherapy then a second course of treatment may be initiated at the discretion of the treating team. The choice of
the second course of pharmacotherapy is at the discretion
of the treating medical team. It is strongly encouraged
that the second course of pharmacotherapy be with the
same regimen as chosen for the initial pharmacotherapy.
If after the second course of pharmacotherapy, the PDA
is still deemed to be symptomatic, then the attending
team will choose their further management plan that may
include: a third course of pharmacotherapy with the same
or a different medication, or surgical PDA ligation, or a
third course of pharmacotherapy, followed by surgical
ligation (if required) or no further treatment.
The participating centres will be allowed to continue
the use of concomitant neonatal interventions such as use
4

of prophylactic NSAIDs (non-steroidal anti-inflammatory
drugs), prophylactic and rescue corticosteroids, blood
product transfusion practices, enteral feeding practices
including use of donor breast milk and probiotics as per
their usual NICU policy. This information is collected
as routine in the CNN database and will be compared
between groups and any imbalances will be adjusted at
the analyses stage.
Patient and public involvement in study design
No patient involved.
Sample size
Sample size estimation is based on the primary hypothesis and the primary outcome: proportion of infants with
failure of primary pharmacotherapy. The best estimates
of pharmacotherapy failure with ibuprofen reported
in RCTs is between 26% and 29%.10 16 However, data
from Canadian observational studies suggest that in the
real-
world primary pharmacotherapy failure rate with
ibuprofen is about 40%.18 19 To reduce the pharmacotherapy failure rate from the current 40% to the best
achievable reported rate of 26%, an absolute reduction
of 14% (relative reduction of 35%) would be required. To
detect a 14% absolute (35% relative) decrease in the rate
pharmacotherapy failure for adjustable dose ibuprofen
group compared with the other treatment groups with
80% power, we will require at least 263 infants in the
adjustable ibuprofen group and 198 infants each in the
remaining treatment groups (~850 infants total who
receive PDA treatment). The two-sided significant level
of 0.05 was used for the sample size estimation, adjusted
for the multiple comparisons. In addition, we will collect
baseline clinical and outcome data on 500 infants who
will not receive PDA treatment (that includes the control
Mitra S, et al. BMJ Open 2021;11:e050682. doi:10.1136/bmjopen-2021-050682
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Figure 1
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Statistical analysis
Since the proposed study is a comparative effectiveness study using prospective observational data, we will
examine and account for potential confounders at the
analyses stage. The analyses will be conducted in two
stages: unit-
level protocol effectiveness analysis and a
secondary drug-dosage effectiveness analysis.
Unit-level protocol effectiveness analysis
In this analysis, the infants will be classified into four
treatment groups (standard dose ibuprofen, adjustable
dose ibuprofen, indomethacin and acetaminophen) as
per their treatment protocol assignment irrespective of
the actual dosage received.
Univariate analyses: We will first compare the baseline characteristics of neonates among the treatment
groups using the χ2 test for categorical variables and F
test (one-way analysis of variance) or Kruskal-Wallis test
as appropriate for continuous variables. The characteristic variables will include maternal variables (age, parity,
hypertension, diabetes, receipt of antenatal steroids,
magnesium sulphate), birth characteristics (mode of
birth, birth outside a tertiary centre, presence of chorioamnionitis), resuscitation characteristics (need for
extensive cardiopulmonary resuscitation) and infant
characteristics (sex, small-for-gestational age, Apgar score
at 5 min, SNAP (score for acute neonatal physiology) II
score, receipt of surfactant, respiratory status at the time
of treatment (mean airway pressure, fraction of inspired
oxygen). To examine the relative effectiveness of the
four treatment strategies, the primary outcome will be
compared pairwise between the treatment groups using
χ2 test. The secondary outcomes will be compared pairwise between the treatment groups using χ2 test, Student’s
t-test or Wilcoxon rank sum test as appropriate.
Multivariable logistic or linear regression: To further
determine differences in the primary and secondary
outcomes between the four groups, we will apply multiple
logistic regression models for each outcome on the treatment groups, adjusted for potential confounders identified from the univariate analyses. To account for the
clustering within units, the generalised estimating equations (GEE) method will be used for the regressions. We
will also examine the variation of the relative effectiveness
of the treatments between sex (or race) by including the
interaction term between treatment and sex (or treatment and race group) in the multiple logistic regression
model for the primary outcome. If the interaction term
is significant, which indicates the relative effectiveness
of the treatment varies between male and female (or
race), subgroup analyses stratified by sex (or race) will be
further conducted to assess the relative effectiveness of
treatment for different sex (or race) if applicable.
Inverse probability weighted (IPW) analyses: As a
sensitivity analysis for the study, we will also examine
Mitra S, et al. BMJ Open 2021;11:e050682. doi:10.1136/bmjopen-2021-050682

the difference in the primary and secondary outcomes
between the treatment groups using propensity score
method with IPW approach.36 The generalised propensity score (GPS), that is, the conditional probability of
receiving a particular level of treatment (standard dose
ibuprofen, adjustable dose ibuprofen, acetaminophen or
indomethacin), will be first estimated using a multiple
multinomial logistic regression model for treatments
(four level dependent variable) on covariates (independent variables) including all available baseline characteristics as mentioned above. As a second step, the multiple
weighted logistic regression models for each outcome,
where the weight is defined as the inverse of the GPS,
will be used to examine the difference in the relative
effectiveness between treatment groups or the association between the clinical outcomes and the treatments.
The GEE approach will be applied for the regressions to
account for the possible clustering within each NICU.
Secondary drug-dosage effectiveness analysis
If a substantial proportion of infants in the adjustable
ibuprofen group are treated within the first 7 days then
they would receive the same dosage as standard dose
ibuprofen. Infants exposed to similar ibuprofen dosages
are likely to have similar outcomes. Hence, any true
difference in effectiveness between standard and higher
doses of ibuprofen may be missed in the former analysis.
As a secondary analysis, the infants will be grouped based
on the actual dosage received during the first course of
treatment, that is, standard ibuprofen dose, adjustable
(higher) ibuprofen dose, acetaminophen and indomethacin. In other words, infants receiving treatment
within the first 7 days in the adjustable ibuprofen group
will be reclassified as standard ibuprofen patients if they
receive standard doses of ibuprofen. The same analytical
approach as described above, including the sub-group
analyses, will be used to examine the relative effect of
treatments on the primary outcome (secondary outcomes
may be related to the entire treatment protocol rather
than dosage of the first treatment course, hence will not
be included in the secondary analysis). A two-sided p<0.05
will be considered statistically significant. We will use SAS
V.9.4 (SAS Institute) and R V.3.4.446 for all analyses.

DISCUSSION
In spite of a large number of RCTs, the most effective and
safe management of PDA in extremely preterm infants
remains controversial. As various treatment strategies
have become well established practices in respective
centres, it would be challenging to conduct large RCTs to
generate effectiveness and safety data without significant
protocol violations. With our proposed CER study, we
intend to analyse real‐world data (defined as data generated during routine clinical practice) in a registry-based
CER study.37 This study also provides a unique opportunity to compare the clinical characteristics and outcomes
of a reference group of extremely premature infants who
5
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and reference groups) to make up a total sample of 1350
infants.
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Anticipated challenges and solutions
We have thought of and planned for challenges likely to
be faced in our study design and execution.
(1) Unreliable data quality: We plan to improve reliability through training and reinforcement of abstractors, range checks at entry level, and random self-audits.
However, we are confident as the CNN database has
shown very high internal consistency and reliability38;
(2) Inconsistency in participation at unit level: We will
focus on stakeholder engagement from the outset,
in-principle agreement by units and collection of data
for protocol deviations; (3) Slow recruitment: With
increasing emphasis on conservative management, the
number of infants being treated for PDA may decline
over time. Based on our current projections even if the
recruitment rate declines by 10%–12% we should still
be able to achieve our sample size by 3 years. Since all
the outcome measures are obtained through routinely
collected clinical data that are entered by data abstractors
after discharge of the patient, COVID-19 related research
restrictions are unlikely to affect data collection and entry
(4) Variation in treatment initiation criteria: We refrained
from prescribing criteria for the initiation of PDA treatment for participating sites so as to mimic a pragmatic
real-
world scenario. Variation in criteria for initiating
treatment may affect response to treatment and clinical outcomes. As long as there is minimal within centre
variation in treatment initiation criteria, we hope that
accounting for site in our analytical model will account
for part of this site related variation; (5) Overlap of treatment protocols: Infants treated early (within 7 days after
birth) in the adjustable dose group may receive the same
dose of ibuprofen as infants in the standard dose group.
If these infants are only analysed as per their treatment
assignment then in spite of being entered in the model
6

as adjustable dose patients, in essence they would be
the same as standard dose patients if they never receive
further treatment. This might lead to a type II error as a
true difference in effectiveness between the standard and
higher doses of ibuprofen would be missed if a substantial
proportion of adjustable dose infants are treated early. To
mitigate this effect we have planned a secondary drug-
dosage effectiveness analysis for the primary outcome
where the infants will be reclassified according to the
actual dosage received rather than their original treatment
assignment; (6) Change in treatment protocol: A centre
that has committed to one particular choice of initial
pharmacotherapy may choose to change to a different
medication based on their local safety and efficacy data,
lack of availability of existing medication or availability
of a new medication. The centre will continue to remain
part of the study as long as their treatment choice still
falls under one of the four predefined choices and the
change occurs at the level of the centre rather than at
the level of the individual practitioner. If a centre uses
multiple different medications as routine initial therapy
based on the choice of the practitioner, that centre will be
excluded from the study (this does not include protocol
deviation for a valid reason such as use of acetaminophen
in infants with contraindications to NSAIDs).
ETHICS AND DISSEMINATION
The study has been approved by the IWK Research Ethics
Board (#1025627) as well as the respective institutional
review boards of the participating centres. All participating centres are part of the CNN patient registry where
routinely collected clinical data, required for this study, is
abstracted from patient charts, and recorded in an anonymised fashion after an infant is discharged from a participating hospital. Therefore, need for written informed
consent from the parents/guardians was waived for this
study.
We will use the following knowledge translation (KT)
strategies for dissemination of our study findings:
Integrated KT: (1) Involvement of stakeholders in
protocol development by organising regular teleconferences prior to submission of proposal; (2) Engagement of
local site investigators for adherence to protocol by organising in-person meetings at CNN’s annual meeting and by
development and dissemination of infographics of study
schema to all participating sites; (3) Troubleshooting
challenges during study period by using the CNN forum
for collaborative learning from ongoing CER projects.
End of study KT: (1) Dissemination of results to the
wider Canadian and international neonatal community
by presenting results at the CNN annual meeting, Canadian Paediatric Society’s annual meeting and Paediatric
Academic Society’s Annual Meeting; (2) Dissemination
of results to hospital administrators by preparing written
summaries, reaching them through our e-newsletters and
further raise awareness regarding our findings through
academic presentations; Increase knowledge in the
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were not diagnosed with PDA versus the ones who were
diagnosed and received treatment for PDA.
The study will be conducted using the principles of
Hypotheses Evaluating Treatment Effectiveness research,
which are designed to evaluate the presence or absence
of a prespecified effect and/or its magnitude.37 We
will follow good practices for the design, analysis, and
reporting of observational real-
world data studies as
outlined by the International Society for Pharmacoeconomics and Outcomes Research.37 Data for the study will
be collected using the CNN database. The CNN is a well-
established patient registry that includes members from
31 hospitals and 17 universities across Canada.31 The
Network maintains a standardised NICU database and
provides a unique opportunity for researchers to participate in collaborative projects. We have gathered stakeholder engagement by conducting a CNN-wide survey
regarding PDA pharmacotherapeutic practices and
exploring the need for such a project. With at least 22
out of the 31 CNN centres participating in this CER, we
believe that evidence generated from this project would
be promptly implemented.
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